Acute Respiratory Infection Clinical Trial
Official title:
Decreasing Antibiotic Prescribing in Acute Respiratory Infections Through Implementation of Nurse Driven Clinical Decision Support
Verified date | October 2023 |
Source | NYU Langone Health |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This study evaluates the effects of a novel integrated clinical prediction tool on antibiotic prescription patterns of nurses for acute respiratory infections (ARIs). The intervention is an EHR-integrated risk calculator and order set to help guide appropriate, evidence-based antibiotic prescriptions for patients presenting with ARI symptoms.
Status | Enrolling by invitation |
Enrollment | 500 |
Est. completion date | August 1, 2025 |
Est. primary completion date | May 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: Clinics: - must be primary care and/or urgent care clinics - should have a minimum of one registered nurse (RN) full time equivalents (FTE) Nurses : - be licensed to see patients and prescribed and/or recommend prescriptions for patients - work a minimum of 0.5 FTE to ensure that they are seeing sufficient numbers of patients to maintain competency - have access to the clinic EHR system, and use regularly as part of patient care Patients: - patients must have been seen at a participating clinic with a complaint of cough or sore throat. - Ages 3-70 will be included for sore throat and ages 18-70 for cough Exclusion Criteria: - are unable or unwilling to provide informed consent - are unable to participate meaningfully in an intervention that involves self-monitoring using software available in English (e.g., due to uncorrected sight impairment, illiterate, non-English-speaking, dementia) - clinics will be excluded if phone call triage of patients with sore throat and cough is not performed by RNs - Nurses will be excluded if they do not work with the clinic EHR as part of their workflow - Patients with a history of chronic lung disease or immunosuppression will be excluded since the CPRs were not validated in these groups |
Country | Name | City | State |
---|---|---|---|
United States | University of Wisconsin | Madison | Wisconsin |
United States | NYU Langone Health | New York | New York |
United States | University of Utah School of Medicine | Salt Lake City | Utah |
Lead Sponsor | Collaborator |
---|---|
NYU Langone Health | National Institute of Allergy and Infectious Diseases (NIAID) |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Participants Who Perceive the iCPR Tool as Useful. | Participants will be interviewed to measure the usefulness of the iCPR tool in prescribing appropriate antibiotics. | Month 6 | |
Primary | Change in number of Acute Respiratory Infection(ARI) encounters | The number of Acute Respiratory Infection(ARI) encounters with inappropriate antibiotic prescription will be measured pre and post-intervention using EHR reports assessing ordering of antibiotics | Baseline, Month 36 | |
Secondary | Change in Job Satisfaction of RNs and physicians | Job satisfaction/ burnout of the RNs and physicians in enrolled clinics will be measured qualitatively with interviews at baseline, 6, and 12 months after implementation | Baseline, Month 6, Month 12 | |
Secondary | Number of nurse triage encounters completed | Adoption of using iCPR tool will be measured by the number of nurse triage encounters completed through extracted EHR data. | Week 2 | |
Secondary | Number of patients requiring repeat healthcare visits | Adoption of using iCPR tool will be measured by the number of patients requiring repeat healthcare visits through extracted EHR data. | week 2 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03943654 -
Improving Nighttime Access to Care and Treatment (Part 2)
|
||
Completed |
NCT05269290 -
Efficacy and Safety of Ingavirin®, Syrup, 30 mg/5 ml, in Children With Influenza and Other Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT06385821 -
A Study to Prove Non-inferior Immunogenicity of Grippol Quadrivalent Compared to Grippol Plus
|
Phase 3 | |
Not yet recruiting |
NCT05902702 -
Isotonic Saline for Children With Bronchiolitis
|
N/A | |
Not yet recruiting |
NCT04525118 -
Wide Scale Monitoring for Acute Respiratory Infection Using a Mobile-based Study Platform
|
||
Completed |
NCT01431469 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 12-48 Months of Age in Salvador, Bahia, Brazil
|
N/A | |
Completed |
NCT00981513 -
Direct and Indirect Benefits of Influenza Vaccination in Schools and Households
|
Phase 4 | |
Recruiting |
NCT06183229 -
Cycloferon for Post-exposure Prophylaxis of Acute Respiratory Viral Infections and Influenza
|
Phase 3 | |
Completed |
NCT03274310 -
FluSAFE: Flu SMS Alerts to Freeze Exposure
|
N/A | |
Completed |
NCT03736096 -
Molecular Diagnosis of Respiratory Viral Infections on Sputum From Cystic Fibrosis Patients
|
||
Completed |
NCT03189537 -
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral Infections
|
Phase 3 | |
Completed |
NCT03028077 -
Effects of GS-3K8 and GINst15 on Acute Respiratory Illness
|
N/A | |
Enrolling by invitation |
NCT01286285 -
Surveillance of Influenza in Paediatric Intensive Care Units in Bavaria
|
N/A | |
Completed |
NCT03840135 -
Efficacy and Safety of Polyoxidonium, Nasal and Sublingual Spray, 6 mg/ml in Children Aged 1-12 Years With ARI
|
Phase 3 | |
Completed |
NCT01488435 -
Efficacy and Tolerance of a Follow-On Formula Fed to Children From 36-48 Months of Age
|
N/A | |
Not yet recruiting |
NCT00545961 -
Middle Meatal Bacteriology During Acute Respiratory Infection in Children
|
Phase 4 | |
Completed |
NCT05273619 -
Efficacy and Safety of XC8, Film-coated Tablets, 40 mg in Patients With Dry Non-productive Cough Against Acute Respiratory Viral Infection
|
Phase 3 | |
Recruiting |
NCT04415827 -
Energy Supply in Athletes and Untrained Persons With Bronchopulmonary Diseases
|
N/A | |
Completed |
NCT03459391 -
Study to Assess Safety, Tolerability and Pharmacokinetics of XC221 in Healthy Volunteers
|
Phase 1 | |
Withdrawn |
NCT04938323 -
Prevention of Acute Respiratory Infection in Taiwanese Institutionalized Elderly
|
Phase 2/Phase 3 |